AIDS: The New Drug War

Smith, Liz
April 1998
Fortune;4/27/1998, Vol. 137 Issue 8, p60
Focuses on the battle between Glaxo Wellcome and Britol-Myers Squibbs over market share for their drugs used to combat AIDS. Glaxo's nucleoside reverse transcriptase inhibitor known as AZT; Bristol-Meyers' introduction of Zerit; Sales figures; The success of Bristol in marketing its drug.


Related Articles

  • Review.  // Campaign;04/02/99, Issue 13, p5 

    Presents news briefs about marketing and advertising in Great Britain as of April 2, 1999. Includes the move by Glaxo Wellcome to court American drug company Bristol Myers Squibb; Launch of fair trade chocolate bar brand by the Body Shop and entertainer Ben Elton; Negotiations for French...

  • Single daily pill for HIV in development. Roehr, Bob // Bay Area Reporter;12/23/2004, Vol. 34 Issue 52, p17 

    Reports that a single pill once a day to treat HIV is the goal set by Bristol-Myers Squibb and Gilead Sciences which have agreed to collaborate. Bristol-Myers Squibb as producer of Sustiva, a non-nucleoside reverse transcriptase inhibitor; Gilead Sciences as producer of Viread and Emtriva, two...

  • Bristol-Myers Squibb.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p32 

    Features the Bristol-Myers Squibb Co., a pharmaceutical manufacturer. Focus areas of its research and development activities; Best-selling products; Drugs that have received approval from the United States Food and Drug Administration.

  • Bristol-Myers Squibb overhauls management.  // Chemical Market Reporter;11/16/98, Vol. 254 Issue 20, p13 

    Reports on the management reorganization of Bristol-Myers Squibb Co. pharmaceutical company in the United States. Creation of a core management team and three councils to oversee company innovation.

  • The Bristol way. Bustos, Sergio R. // Latin Trade (English);Jan1999, Vol. 7 Issue 1, p26 

    Focuses on United States-based pharmaceutical firm Bristol-Myers Squibb's plan to increase sales in Latin America. Acquisition of local companies; Formation of alliances; Revenues in 1997.

  • Strong profits.  // Crain's New York Business;01/25/99, Vol. 15 Issue 4, p46 

    Announces the profit posted by drug and beauty care products company Bristol-Myers Squibb Co. in the fourth-quarter of 1998.

  • Bristol-Myers Squibb Company:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p42 

    A reference entry for Bristol-Myers Squibb Co., a pharmaceutical company, is presented.

  • Drugs to Be Sole Focus For Bristol-Myers.  // Mergers & Acquisitions: The Dealermaker's Journal;Jul2001, Vol. 36 Issue 7, p25 

    Reports on Bristol-Myers Squibb Co.'s plans to sell its non-core business units to devote its attention to the pharmaceutical sector. Profitability of the company's non-core units; Bristol-Myers' presence in several business sectors.

  • Bristol-Myers Squibb's locally made products sell $4.2 billion in 2002. Martinez, Marialba // Caribbean Business;3/20/2003, Vol. 31 Issue 11, p12 

    Reports on the financial performance of drug company Bristol-Myers Squibb for 2002. Total reported earnings; Restated financial results for the years 1999 through 2001; Top growth products.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics